Establishment of a positive-readout reporter system for siRNAs by Liu, Wei-li et al.
 
©The Authors | Journal of RNAi and Gene Silencing | June 2009 | Vol 5, No 1 | 331-338 | OPEN ACCESS 
331 
SHORT REPORT  
 
 
Establishment  of  a  positive-readout  reporter  system  for 
siRNAs 
 
Wei-li Liu, Douglas P Owen, Kerry D Fisher, Leonard W Seymour and Mark Stevenson* 
 
Department of Clinical Pharmacology, Old Road Campus Research Building, University of Oxford, Old Road Campus 
off Roosevelt Drive, Headington, Oxford OX3 7DQ, UK 
 
*Correspondence to: Mark Stevenson, Email: mark.stevenson@clinpharm.ox.ac.uk Tel: +44 1865 617041, Fax: +44 
1865 617028 
 
Received 28 August 2008; Revised 20 May 2009; Accepted 27 May 2009; Published online 12 June 2009 
 
J RNAi Gene Silenc (2009), 5(1), 331-338 
 
©  Copyright  The  Authors:  This  is  an  open  access  article,  published  under  the  terms  of  the  Creative  Commons 
Attribution  Non-Commercial  License  (http://creativecommons.org/licenses/by-nc/2.0/uk/).  This  license  permits  non-
commercial use, distribution and reproduction of the article, provided the original work is appropriately acknowledged 
with correct citation details. 
 
ABSTRACT 
 
The use of small interfering RNA molecules for therapeutic applications requires development of improved 
delivery systems, a process that would be facilitated by a non-invasive positive-readout mouse model for 
studying siRNA pharmacodynamics. Positive readout would yield better signal/noise ratios than existing 
negative-readout systems. We have engineered a positive-readout luciferase reporter system, activated by 
successful  delivery  of  siRNA  targeting  the  lac  repressor.  Co-transfection  of  a  plasmid  expressing  lac 
repressor and a plasmid expressing firefly luciferase under the control of an RSV promoter, containing two 
lac  operator  sites,  resulted  in  5.7-fold  lower  luciferase  activity  than  luciferase-encoding  plasmid  alone.  
Inhibition was reversed following addition of synthetic inducer, IPTG, which elevated luciferase expression 
to  normal  levels  and  confirmed  functionality  of  the  lac  operon.  Delivery  of  1nM  siRNA  targeting  lac 
repressor to repressor/reporter co-transfected cells was sufficient to fully restore luciferase expression to 
levels observed in the absence of repressor. Maximum expression was observed after 48hr, with a rapid 
decrease thereafter due to the short half life of luciferase.  The luciferase positive-readout reporter system is 
therefore a dynamic indicator of successful RNAi delivery in vitro and could be adapted to generate a 
transgenic mouse capable of reporting RNAi activity non-invasively in vivo. 
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INTRODUCTION 
 
RNA  interference  (RNAi)  is  a  powerful  approach  for 
suppressing  expression  of  specific  genes  in  mammalian 
cells,  either  as  a  basic  research  tool  to  elucidate  gene 
function, or in a clinical setting for therapeutic application 
(Fire et al, 1998; Tuschl et al, 1999; Elbashir et al, 2001).  
Therapeutic  strategies  eliciting  RNAi  involve  targeting 
exogenous  genes  from  pathogens  or  endogenous  genes 
playing a role in the disease process.  There are two basic 
strategies; a drug approach where siRNA is administered 
in  its  final  form,  or  a  gene  therapy  approach  where 
precursor  hairpin  siRNAs  are  expressed  from  viral  (or 
non-viral) vectors providing longer-term expression. The 
first  strategy  is  simpler  and  avoids  problems  associated 
with  gene  delivery,  such  as  antibody-mediated  vector 
neutralization,  or  restrictive  effects  of  the  intact  nuclear 
membrane in non-mitosing cells. 
 
However,  effective  delivery  of  therapeutic  siRNA  to 
disease target cells remains a major challenge. Although, 
local delivery can yield promising results, for example in 
the  treatment  of  wet  age-related  macular  degeneration 
involving  local  intravitreal  injections  with  Bevasiranib 
(Acuity  Pharmaceuticals),  which  is  in  Phase  III  clinical 
trials; delivery of siRNA to reach disseminated or body-
wide  targets  faces  particular  challenges.  These  include 
inefficient  cellular  up-take,  inadequate  tissue  
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biodistribution, limited bioavailability and poor long-term 
stability  of  siRNA  molecules  in  the  blood  stream  and 
cytosol. A wide range of strategies have been evaluated for 
delivery  of  siRNA  to  non-local  sites,  including 
hydrodynamic  injection  (Lewis  and  Wolff,  2005;  Lewis 
and  Wolff,  2007),  or  covalent  conjugation  of  siRNA 
molecules to; cholesterol (Soutschek et al, 2004), targeting 
peptides  (Moschos  et  al,  2007)  or  antibodies  leading  to 
receptor  mediated  endocytosis  (Song  et  al,  2005).  
Delivery can also be mediated by siRNA-binding vectors 
including lipids (Hassani et al, 2005; Bollerot et al, 2006; 
Santel et al, 2006), cationic polymers (Kataoka et al, 2005; 
Leng et al, 2007; Oishi et al, 2007) and a variety of other 
carriers  (Minakuchi  et  al,  2004;  Morrissey  et  al,  2005; 
Takeshita et al, 2005; Kim et al, 2006; Zimmermann et al, 
2006). Despite the elegance of some of these approaches, 
critical assessment of utility is frequently confounded by 
the  absence  of  effective  systems  for  evaluation  of 
successful siRNA delivery and activity.  
 
Methods to determinate in vivo biodistribution of siRNA 
molecules include fluorescence (Dunne et al, 2003; Larson 
et  al,  2007),    radioactivity  (van  de  Water  et  al,  2006; 
Zimmermann et al, 2006), or complexation with magnetic 
nanoparticles  (Medarova  et  al,  2007).  However,  these 
techniques have limitations, notably the label may alter the 
properties  of  the  vector,  affecting  the  pharmacokinetics 
(PK), and catabolism of siRNA (and possible anabolism of 
the labelled moiety), that may impose a fairly short time 
window for useful interpretation of results. Furthermore, 
the use of radioactivity is becoming less popular, while the 
application of magnetic nanoparticles needs expensive and 
specialist equipment. 
   
In addition, anatomical biodistribution of siRNA is not a 
good indicator of biological activity, since siRNA action is 
crucially dependent on transfer through the cell membrane. 
Techniques  to  assess  siRNA  activity  (or  ‘pharmaco-
dynamics’) are dependent on the nature of the molecular 
target.  Where  siRNA  targets  mRNA  encoding  specific 
enzymes,  pharmacodynamics  can  be  assessed  by 
measuring inhibition of enzyme activity in isolated organs, 
tissues  or  cells.  Unfortunately,  such  assays  are  highly 
invasive, preventing time-resolved repeated assessment in 
the same animals, and it can be very easy for researchers 
to  miss  spatially  off-target  effects.  In  principle,  every 
target-expressing cell type in the body must be evaluated 
to assess whether siRNA activity is truly restricted to the 
intended target. To address this transgenic reporter mice or 
disease  models  that  ubiquitously  or  selectively  express 
reporter genes such as GFP or luciferase, can be employed 
to test the silencing effect of siRNA delivery (Palliser et 
al,  2006).  However,  such  systems  are  not  ideal  since 
models  generating  selective  expression  of  the  target 
mRNA in a specific organ will skew the data to give a 
desired outcome; whilst ubiquitously expressing ‘negative-
readout’  models  suffer  from  high  levels  of  background 
with intrinsic poor signal to noise ratio. 
 
There is therefore a need for an animal model that reveals 
successful  siRNA  delivery,  effectively  a  pharmaco-
dynamic reporter model. Ideally this would involve the use 
of  non-invasive  readouts  that  allow  time-based 
measurement of body-wide effects of siRNA. In order to 
facilitate this aim we have developed a positive-readout in 
vitro  model  in  which  RNAi  activity  is  reported  by 
luciferase expression.  It is based on the well-characterized 
E. coli lac operon (Jacob and Monod, 1961), where in the 
absence  of  lactose  the  Lac  repressor  (LacI)  binds  as  a 
homotetramer to the lac operators (lacO) located  within 
the  promoter  region,  blocking  transcription  of  the  lac 
operon.  Lactose  causes  a  conformational  change  in  the 
repressor causing it to vacate the operators allowing RNA 
polymerases  to  gain  access  to  the  promoter  and  initiate 
transcription.  When  the  repressor  is  removed  from  the 
operator,  transcription  from  the  lac  operon  resumes.  
Introduction of siRNA targeting the lac repressor mRNA 
will reduce levels of repressor protein allowing expression 
of a reporter gene, in our case luciferase, downstream of a 
lacO-containing  promoter  (Figure  1a),  thus  giving  a 
positive readout of RNAi activity. 
 
An inducible expression system based on the lac operon 
has  recently  been  developed  in  mice  (Scrable  and 
Stambrook, 1997; Cronin et al, 2001; Ryan and Scrable, 
2004).  We  demonstrate  here  that  an  inducible  system 
based  on  the  lac  operon  can  be  used  to  monitor  RNAi 
activity and has the potential to be developed for use as a 
pharmacodynamic indicator of siRNA activity. 
 
MATERIALS AND METHODS 
 
Cell culture 
SiHa human cervical squamous cell carcinoma cells were 
maintained  in  Dulbecco’s  Modified  Eagle  Medium 
(DMEM) (Invitrogen, Paisley, UK) supplemented with 10% 
(v/v)  foetal  calf  serum  (FCS)  (Sigma,  Gillingham,  UK), 
1.0mM sodium pyruvate, 0.1mM non-essential amino acids, 
50U/ml penicillin and 50µg/ml streptomycin.  PC-3 human 
prostate adenocarcinoma cells were maintained in DMEM, 
4.5g/l glucose, 2mM glutamine (PAA Laboratories GmbH, 
UK), supplemented with 10% (v/v) FCS.   
 
Design of siRNA against LacI repressor 
The  following  siRNAs  were  designed  using  the  Custom 
siRNA  Design  Tool  provided  by  Dharmacon  Inc 
(http://www.dharmacon.com/DesignCenter/DesignCenterP
age.asp), an algorithm based on the guidelines of Reynolds 
et  al  (Reynolds  et  al,  2004),  and  were  synthesized  by 
MWG, London, UK. BLAST analysis  was performed to 
eliminate sequences with off-target homologies. 
 
siRNA targeting lacI repressor mRNA (silacI): 
 
sense: 5’-AUAUCUCACUCGCAAUCAAdTdT-3’, 
antisense:  5’UUGAUUGCGAGUGAGAUAUdTdT-3’ 
 
siRNA targeting GFP (siGFP): 
 
sense: 5’-GCAAGCUGACCCUGAAGUUCAU-3’, 
antisense: 5’-GAACUUCAGGGUCAGCUUGCCG-3’  
 
Construction  of  lac  operator-repressor  plasmid 
expression vectors   
The lac operator-repressor system employed in this study 
comprises  two  components  based  on  the  LacSwitch  II 
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Figure 1.  A. Utilization of the lac-operon to generate a positive-readout reporter model for the detection of siRNA.  a) In the 
uninduced state lac repressor (lacI) is transcribed and translated into protein (LacI), which binds lac operators (lacO) located within 
the promoter and an SV40 intron upstream of the luciferase gene, suppressing reporter gene expression. b) IPTG alters the 
conformation of LacI preventing it from binding to lacO, allowing RSV driven luciferase expression. c) siRNA specifically targeting 
lacI mRNA causes repressor protein levels to fall permitting RSV driven luciferase expression.  B. Plasmid vectors employed in the 
inducible luciferase expression system. pOPRSVILuc was created by excision of the luciferase reporter gene from pGL-3 Basic by 
XbaI and XhoI restriction digestion and ligated into the multiple cloning site of pOPRSVI/MCS.  pOPRSVI-Luc contains two lac 
operator binding sites (lacO1 and lacO2) within the RSV promoter and the SV40 intron. pCMV-LacI (a component of the LacSwitch 
Inducible System) expresses lac repressor from a CMV promoter; pEF1αLacI was created by replacing the CMV promoter with the 
human elongation factor 1 alpha (EF1α) promoter excised from pEF1αLux.G by AflII and BalII digestion.  
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Inducible  Mammalian  Expression  System  (Stratagene,  La 
Jolla,  CA,  USA).  Component  one,  the  pCMV-LacI 
eukaryotic lac repressor expression vector, was modified by 
replacing  the  CMV  promoter  with  the  human  elongation 
factor 1α (EF1α) promoter excised from pEF1αLUX.G (a 
gift from Dr Deborah Gill, University of Oxford) by AflII 
and  BalII  restriction  digest.  Component  two,  the 
pOPRSVI/MCS  operator  vector,  comprises  an  RSV 
promoter into which are embedded two lac operator binding 
sites  upstream  of  a  multiple  cloning  site.  The  firefly 
luciferase  gene  was  excised  from  pGL3-Basic  (Promega, 
Southampton, UK) using XbaI and XhoI restriction enzymes 
and inserted into the MCS of pOPRSVI/MCS to generate 
the pOPRSVI-Luc reporter vector. 
 
Transfection of lac-operator-repressor system 
To  confirm  the  inducible  nature  of  the  lac-operator-
repressor  expression  system,  5x10
4  SiHa  cells  were 
transfected in triplicate with 0.2µg pOPRSVI-Luc alone or 
together with either 0.2 µg pEF1α-LacI or various amounts 
(ranging  from  0.02  to  0.2µg)  of  pCMV-LacI,  using 
DOTAP  liposomal  transfection  agent  (Sigma-Aldrich, 
Gillingham, UK) (w:w ratio of 5:1) in serum free medium 
according  to  the  manufacturer’s  instructions.  Serum 
containing medium was added to cells after 4hr. After 39hr 
selected cells were treated with 5mM IPTG (EF1α-LacI) or 
25mM  IPTG  (pCMV-LacI).  Forty  eight  hours  after 
transfection cells were harvested and luciferase expression 
measured  using  Luciferase  Assay  Reagent  (Promega, 
Southampton,  UK)  and  a  luminometer  (Berthold, 
Harpenden,  UK).  Expression  in  each  sample  was 
normalized for total protein content.  
 
Confirmation  of  lac  repressor  silencing  by  western 
blotting 
To examine silencing from siRNA designed to target the 
lac repressor, 5x10
5 PC-3 cells were transfected with 2µg 
pEF1α-LacI using Lipofectamine (Invitrogen, Paisley, UK) 
according  to  the  manufacturer’s  instructions.  After  2hr 
100nM siRNA targeting siLac or siGFP complexed with 
Oligofectamine  (Invitrogen,  Paisley,  UK)  was  added  to 
cells.  Serum  containing  medium  was  added  to  cells  4hr 
later.  Forty  eight  hours  after  transfection,  total  cellular 
protein  was  extracted  using  M-PER  solution  (Pierce 
Biotechnology,  Rockford,  IL,  USA)  containing  protease 
inhibitor  cocktail  (Roche,  Welwyn  Garden  City,  UK). 
Protein concentration was determined by advanced protein 
assay reagent (Cytoskeleton, Denver, CO, USA); 30µg of 
protein was loaded on a 12% (w/v) SDS-PAGE gel. The 
proteins  were  transferred  to  a  PVDF  membrane  and 
blocked in 5% (w/v) dried milk in Tris buffered saline pH 
7.4, 0.1% (v/v) Tween 20 (TBST) at room temperature for 
90min. The blot was then washed three times with TBST 
and  incubated  with  mouse  anti-LacI  clone  9A5  primary 
antibody  (Millipore  UK  Ltd,  Watford,  UK)  diluted  1  in 
1000  at  room  temperature  for  2hr.  The  blot  was  then 
washed  three  times  with  TBST  and  incubated  with  goat 
anti-mouse IgG-HRP secondary antibody (Dako, Ely, UK) 
diluted 1 in 5000 at room temperature for 1hr. The blot was 
washed  and  the  bands  visualized  by  chemiluminscence 
using  LumiGLO  (KPL,  Gaithersburg,  MD,  USA)  on  a 
ChemiImager  (Alpha  Innotech  Corp,  San  Leandro,  CA, 
USA), and analysed using Fluorchem 8000 software. Each 
blot  was  stripped  and  re-probed  with  sc-5286  anti-α-
tubulin antibodies (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) diluted 1:1000 as a protein loading control. 
 
Restoration of luciferase activity following addition of 
siRNA against LacI repressor 
To  assess  the  effect  of  siLacI  on  the  inducible  reporter 
system, 4x10
4 PC-3 cells  were transfected  with i) 200ng 
pOPRSVILuc,  ii)  200ng  pOPRSVILuc  and  200ng 
pEF1αLacI,  or  iii)  200ng  pOPRSVILuc  and  200ng 
pEF1αLacI plus various doses of siRNA (siLacI or siGFP) 
ranging  from  1  to  50nM  final  concentration,  using 
Lipofectamine (Invitrogen, Paisley, UK). Serum containing 
medium  was  added  to  cells  after  4hr.  5mM  IPTG  was 
added  to  various  control  wells  24hr  prior  to  measuring 
luciferase activity which was measured 24, 48 or 72hr post 
transfection. 
 
RESULTS 
 
Generation of an inducible luciferase reporter system 
To  generate  a  functional  inducible  expression  system, 
permissive to regulation by siRNA (Figure 1a), the amount 
of repressor protein generated inside cells is crucial. Too 
high and the siRNA will be ineffective, while too low and 
the system will be leaky with high background luciferase 
activity. Consequently both the optimal ratio of repressor 
plasmid to operator plasmid, and selection of a promoter of 
appropriate strength to drive lacI, must be determined. 
 
Components  of  the  LacSwitch  II  Inducible  Mammalian 
Expression  System  (Stratagene,  La  Jolla,  CA,  USA) 
comprising the LacI-expression vector (pCMV-LacI) and 
lac-operator  containing  vector  (pORSVI/MCS)  were 
utilized for this study.  Firefly luciferase was excised from 
pGL-3  Basic  (Promega,  Southampton,  UK)  and  inserted 
into the multiple cloning site of pOPRSVI/MCS, such that 
it was under the control of the respiratory syncytial virus 
(RSV) promoter to generate pOPRSVI/Luc (Figure 1b). 
  
Luciferase  activity  from  pOPRSVI-Luc  transfected  SiHa 
cells was down-regulated in a dose-responsive manner when 
co-transfected with pCMV-LacI (Figure 2).  Addition of the 
synthetic  inducer  isopropyl  β-D-thiogalacto-pyranoside 
(IPTG) causes a conformational change in the repressor by 
decreasing  its  affinity  for  the  operator.    However  25mM 
IPTG had little effect on the level of luciferase expression 
when pCMV-LacI was delivered at doses greater than 20 ng. 
In fact even when pCMV-LacI was present at one tenth of 
the amount of pOPRSVI/Luc, the addition of IPTG restored 
only 25% of the luciferase activity generated in the absence 
of repressor.  This would suggest that either the repressor 
protein  is  over-expressed  when  under  the  control  of  the 
CMV promoter for optimal inducibility, or the presence of 
the  CMV  promoter  may  affect  expression  from  the  RSV 
promoter in pOPRSVILuc (Farr, 1991). 
 
We  therefore  generated  a  second  repressor  construct  in 
which lacI was under the control of a weaker promoter, 
namely  human  elongation  factor  alpha  (pEF1α-LacI) 
(Figure  1b).  Western  blot  analysis  of  transfected  CaSki 
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Figure 2.  Testing the inducible nature of the lac-operator-repressor system.  5x10
4 SiHa cells were transfected in triplicate with 
either 0.2 µg pOPRSVI-Luc alone or co-transfected with various amounts of pCMV-LacI as indicated.  After 39 h selected cells were 
treated with 25 mM IPTG and incubated for a further 9 h prior to luciferase analysis.  Statistical analysis was performed using the 
Kruskal-Wallis test and Mann Whitney tests due to heterogeneity of variances (*, p< 0.05; ns = not significant). 
 
 
 
cells confirmed lower Lac expression from the pEF1αLacI 
construct  than  CMVLacI  (data  not  shown).  Functional 
repression  from  pEF1αLacI  was  shown  following  co-
transfection  of  SiHa  cells  with  an  equal  amount  of 
pORSVI-Luc  resulted  in  5.7-fold  lower  luciferase 
expression compared with cells transfected with pORSVI-
Luc alone (Figure 3). However the addition of only 5mM 
IPTG to co-transfected cells was sufficient to fully restore 
luciferase activity to the level observed in non-repressed 
cells.  Co-transfection of cells with a two-fold excess of 
pEF1αLacI did not result in any greater repression (data 
not shown). 
 
Down regulation of Lac repressor protein by siRNA  
Having  successfully  generated  an  inducible  luciferase 
expression  system,  siRNA  targeting  the  lac  repressor 
mRNA (siLacI) was designed and tested using PC-3 cells 
transfected with pEF1αLacI. Two hours following plasmid 
delivery 100 nM siLacI or non-target siGFP was added to 
cells.  The  application  of  siLacI  resulted  in  undetectable 
levels of repressor protein by western blotting after 48hr 
(Figure 4a). In contrast transfection of siGFP had only a 
minor effect on the level of repressor protein. 
 
siLac restores luciferase activity in the inducible system 
Having demonstrated the siRNA was functional in down 
regulating  the  target  LacI  repressor  protein,  we  co-
administered siLacI to PC-3 cells transfected with the two 
components  of  the  inducible  expression  system  in  an 
attempt to induce luciferase activity. siRNA and plasmid 
DNA  were  prepared  in  the  same  liposomal  complex  to 
ensure cells received both nucleic acids. The co-delivery of 
the  repressor  plasmid  with  the  reporter  plasmid  reduced 
luciferase expression, while addition of 5mM IPTG fully 
alleviated repression as previously described (Figure 4b).  
IPTG  had  no  effect  on  luciferase  expression  from  cells 
transfected  with  pOPRSVILuc  alone.  Delivery  of  1nM 
siLacI  was  sufficient  to  fully  restore  luciferase  activity 
compared with cells transfected with the inducible system 
alone. In contrast delivery of a siRNA targeting GFP failed 
to increase luciferase activity at low doses, although non-
specific activity was observed at 50nM siGFP. These data 
confirm that the induced luciferase activity was due to a 
sequence specific down-regulation of the Lac repressor. 
 
Luciferase  has  a  half  life  of  3-4hr  in  mammalian  cells, 
consequently reduced mRNA levels are rapidly converted 
into  lower  protein  levels  and  as  a  result  it  is  a  more 
dynamic  indicator  than  longer  lived  reporters  such  as 
green fluorescent protein. This is important for time based 
measurements since once siLacI is exhausted the effects 
can be detected by the rapid disappearance of luciferase 
signals.  Indeed  following  IPTG  induction  or  siLacI 
delivery  to  cells  transfected  with  the  inducible  system, 
luciferase  expression  decreased  rapidly  between  48  and 
72hr  (Figure  4c).  This  decline  in  luciferase  activity 
suggests that the level of lac repressor inside cells is being 
re-established  and  is  therefore  available  to  occupy  lacO 
sites repressing luciferase activity.  
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Figure 3.  Luciferase activity repressed by EF1α-LacI expression can be fully restored by   IPTG induction.  5x10
4 SiHa cells were 
transfected with 0.2µg pOPRSVI-Luc alone or co-transfected with 0.2 µg pEF1α-LacI.  After 39hr selected cells were treated with 
5mM IPTG for 9hr prior to analysing cells for luciferase activity.  Statistical analysis was performed using the Kruskal-Wallis test 
and Mann Whitney tests due to heterogeneity of variances (*, p< 0.05; ns = not significant). 
 
 
 
 
DISCUSSION 
 
By employing the lac operon system we have successfully 
induced  luciferase  expression  following  application  of 
siRNA targeting lacI mRNA, and thus generated a positive 
readout from RNA interference. Correct functioning of the 
regulatory system was achieved using the relatively weak 
EF1α promoter to drive repressor protein expression, with 
complete  restoration  of  luciferase  expression  following 
IPTG  administration.    In  contrast  the  CMV  promoter 
driven repressor resulted in only 25% restoration on IPTG 
addition, suggesting LacI overexpression or the presence of 
the  CMV  promoter  affected  expression  from  the  RSV 
promoter (Farr, 1991). This issue could be resolved with 
the use of an internal control such as a Renilla luciferase 
driven from the same RSV promoter. The signal to noise 
ratio (i.e., the difference in expression when fully induced 
by IPTG and the uninduced state) increased from 3.7 for 
CMV to 6.9 for EF1α.  
 
siLacI potently silenced repressor protein expression when 
delivered to cells 2hr after  DNA delivery, albeit at  high 
concentration (100nM) (Figure 4a). However when siRNA 
and DNA were delivered in the same complex in order to 
ensure  the  same  cells  were  transfected,  siLacI 
concentration  as  low  as  1nM  fully  restored  luciferase 
activity (Figure 4b). This demonstrates efficacy at the low 
siRNA  concentrations  that  would  be  expected  in  target 
cells  following  in  vivo  delivery.  It  may  be  possible  to 
further  enhance  silencing  activity  and  specificity  by 
engineering the 3’ UTR of the lac repressor with custom 
sites as targets for effective siRNAs. 
 
The  fact  that  following  a  burst  of  luciferase  activity  on 
IPTG administration the luciferase activity fell rapidly over 
time, falling to around 50% of the level measured at 48hr at 
72hr, demonstrates the short half-life of luciferase and its 
suitability as a dynamic indicator of siRNA activity inside 
cells. 
 
Although  the  transient  transfection  studies  demonstrated 
proof of principle using a lac operator-repressor based on 
bacterial sequences, the system fails in a transgenic mouse 
due  to  CpG  methylation  and  silencing  (Scrable  and 
Stambrook, 1997).  Instead Cronin et al. have developed a 
mouse by modifying codon usage and structure such that 
the lac repressor transgene resembled a typical mammalian 
gene (Scrable and Stambrook, 1997; Cronin et al, 2001).  
Scrable  and  co-workers,  following  mammalianisation  of 
the lac operon codon usage, generated two lines bearing 
either the repressor protein (driven from a 4.3kb fragment 
of  human  β-actin  promoter  containing  a  rabbit  globin 
spacer, thus avoiding silencing of strong viral promoters in 
mice),  or  a  tyrosinase  transgene  under  the  control  of  an 
inducible  promoter.  Subsequent  crossing  of  the  lines 
generated double transgenics, in which pigmentation of the 
mouse  was  controlled  by  administration  of  IPTG  in  the 
drinking water (Cronin et al, 2001). More recently, Ryan 
and  Scrable  have  successfully  regulated  a  luciferase 
reporter  gene  with  the  lac  operon  system  (Ryan  and  
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Scrable, 2004).  Luciferase was placed under the control of 
the  Huntingdon  promoter,  HD  being  expressed 
ubiquitously throughout life, in which were embedded two 
lacO sites. Using the Ivis system (Xenogen) and a sensitive 
CCD  camera  to  detect  positive  signals,  allowed 
visualization of the dynamics of gene expression in real-
time and in a non-invasive manner. According to Xenogen 
the  camera  is  capable  of  detecting  light  <100 
photons/s/cm
2.  Since  autoluminescence  of  mice  is  about 
1000  photons/s,  Xenogen  estimate  in  vivo  sensitivity  is 
around 100 subcutaneous high-expressing transduced cells. 
Since one centimetre of depth will attenuate the signal 10 
fold,  sensitivity  for  deep  tissue  is  around  1000  high 
expressing  cells.    Where  issues  of  sensitivity  may  be 
problematic, organs could be dissected and imaged outside 
the  carcass,  whilst  alternative  methods,  such  as 
immunohistochemistry  for  luciferase  protein  or  protein 
extraction  and  western  blotting  could  be  employed  to 
confirm findings. 
 
We envisage such a system could be employed to report 
the  silencing  efficacy  of  siRNA  and  its  real-time 
biodistribution. This reporter mouse would be an important 
tool  providing  important  insights  into  the  development 
novel siRNA delivery systems and improve the pipeline of 
molecules available for therapies. 
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Figure 4.  Silencing of lac repressor restores luciferase expression.  A. 5x10
5 PC-3 cells were transfected with 2µg of pEF1α-LacI 
vector using Lipofectamine.  After 2hr 100nM siLacI or siGFP complexed with Oligofectamine were added to cells. Expression of  
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LacI was analysed 48hr after DNA delivery by western blotting using an anti-LacI antibody diluted 1/1000.  Expression of α-tubulin 
was determined using an anti-α-tubulin antibody diluted 1/1000 as a loading control. [Key: Lane 1; mock, Lane 2; pEF1αLacI, Lane 
3; pEF1αLacI + siLacI, Lane 4; pEF1αLacI + siGFP]. B. 4x10
4  PC-3 cells were transfected with i) 0.2µg pOPRSVI-Luc alone 
(white bars),  ii) 0.2µg pOPRSVILuc and 0.2µg pEF1α-LacI (black bars) or iii) 0.2µg pOPRSVILuc, 0.2µg pEF1α-LacI and various 
doses of siRNA  as indicated (siLacI diagonal striped bars, siGFP vertical striped bars). Control cells received 5mM IPTG after 24hr 
and luciferase expression was measured after 48hr. C. 4x10
4 PC-3 cells were co-transfected with 0.2µg pOPRSVI-Luc and 0.2µg 
pEF1α-LacI in the presence or absence of siRNA. Selected cells were exposed to 1nM siLacI or 1nM siGFP and luciferase activity 
measured at the indicated time point after siRNA delivery. 
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